The right to Trial initiative was established after research from the Leukaemia Foundation found that one in five blood cancer patients tried to access a clinical trial but there either weren’t any trials available or they weren’t eligible. With less than 30 per cent having access to genetic and genomic testing to inform their diagnosis and treatment.
The initiative will allow 1,800 blood cancer patients access to emerging treatments specific to the genetic markers relevant to their individual disease. Under current clinical trial schemes, these same patients would be waiting potentially five to ten years longer for access to trials.
Current figures by the Australian Institute of Health and Welfare 2019 Cancer in Australia Report, predicted over 17,000 new cases of blood cancer will be diagnosed this year. With more than 6,700 dying from a blood cancer disease in the same period. Partly due to the ongoing issue that whilst game-changing treatments are being developed, there are often too slow for patients to fully utilise their potential.